MX2021013338A - Método para tratar la tos usando un compuesto de diaminopirimidina. - Google Patents

Método para tratar la tos usando un compuesto de diaminopirimidina.

Info

Publication number
MX2021013338A
MX2021013338A MX2021013338A MX2021013338A MX2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A
Authority
MX
Mexico
Prior art keywords
diaminopyrimidine compound
treating cough
cough
compound
treating
Prior art date
Application number
MX2021013338A
Other languages
English (en)
Spanish (es)
Inventor
Jin Wang
Zhou Lan
Yanping Zhao
Hongjun Wang
Huai Huang
Liying Zhou
Yanan Liu
Yuanyuan Jiang
Huining Liang
Ran An
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of MX2021013338A publication Critical patent/MX2021013338A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021013338A 2019-04-30 2020-04-29 Método para tratar la tos usando un compuesto de diaminopirimidina. MX2021013338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085180 2019-04-30
PCT/CN2020/087686 WO2020221274A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗咳嗽的方法

Publications (1)

Publication Number Publication Date
MX2021013338A true MX2021013338A (es) 2022-01-24

Family

ID=73029672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013338A MX2021013338A (es) 2019-04-30 2020-04-29 Método para tratar la tos usando un compuesto de diaminopirimidina.

Country Status (11)

Country Link
US (1) US20220211703A1 (https=)
EP (1) EP3960179B1 (https=)
JP (1) JP7665529B2 (https=)
KR (1) KR102935436B1 (https=)
CN (1) CN114007619B (https=)
AU (1) AU2020265327B2 (https=)
BR (1) BR112021021600A2 (https=)
MX (1) MX2021013338A (https=)
SG (1) SG11202111877TA (https=)
TW (1) TWI736243B (https=)
WO (1) WO2020221274A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7207634B2 (ja) 2017-11-01 2023-01-18 ベイジン タイド ファーマシューティカル カンパニー リミテッド P2x3及び/又はp2x2/3受容体アンタゴニスト、それを含む医薬組成物及びその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1930135B (zh) * 2004-03-05 2011-12-28 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶
CA2619919C (en) * 2005-09-01 2014-04-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
AU2007304280B2 (en) 2006-10-04 2013-01-31 F. Hoffmann-La Roche Ag Process for synthesis of phenoxy diaminopyrimidine derivatives
RU2650118C2 (ru) * 2013-08-23 2018-04-09 Афферент Фармасьютикалз Инк. Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
KR20180054843A (ko) * 2015-09-29 2018-05-24 애퍼런트 파마슈티컬스 인크. 기침 치료에 사용하기 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조정제
MA43821A (fr) * 2016-03-14 2018-11-28 Afferent Pharmaceuticals Inc Pyrimidines et variantes de celles-ci, et leurs utilisations
MA44489A (fr) * 2016-03-25 2019-01-30 Afferent Pharmaceuticals Inc Pyrimidines et variants de celles-ci, et leurs utilisations
JP7207634B2 (ja) 2017-11-01 2023-01-18 ベイジン タイド ファーマシューティカル カンパニー リミテッド P2x3及び/又はp2x2/3受容体アンタゴニスト、それを含む医薬組成物及びその使用

Also Published As

Publication number Publication date
JP7665529B2 (ja) 2025-04-21
EP3960179A4 (en) 2023-01-25
US20220211703A1 (en) 2022-07-07
CN114007619A (zh) 2022-02-01
SG11202111877TA (en) 2021-11-29
TW202106302A (zh) 2021-02-16
CA3138780A1 (en) 2020-11-05
KR102935436B1 (ko) 2026-03-05
EP3960179A1 (en) 2022-03-02
BR112021021600A2 (pt) 2022-01-04
EP3960179B1 (en) 2026-03-18
CN114007619B (zh) 2024-08-06
TWI736243B (zh) 2021-08-11
AU2020265327B2 (en) 2025-09-11
AU2020265327A1 (en) 2021-12-16
KR20220007620A (ko) 2022-01-18
JP2022530890A (ja) 2022-07-04
WO2020221274A1 (zh) 2020-11-05

Similar Documents

Publication Publication Date Title
PH12022551585A1 (en) Substituted tricyclic compounds
NZ756231A (en) A novel isoindoline derivative, a pharmaceutical composition and use thereof
MX2013012588A (es) Inhibidores de cinasa.
PH12021551844A1 (en) INVENTION-JAK Inhibitor And Preparation Method Thereof
SA518391836B1 (ar) تيتراهيدروبيرانيل أمينو-بيرولوبيريميدينون وطرق استخدامه
BR112021026214A2 (pt) Método para tratamento de fibrose pulmonar idiopática
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
EA033689B9 (ru) Ингибиторы g12c kras
EP4592275A3 (en) Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
PH12018500777A1 (en) Farnesoid x receptor modulators
TN2016000581A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
AU2015293541B2 (en) Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
ZA202311035B (en) Phosphonyl derivative, and composition and pharmaceutical application thereof
IN2014KN00948A (https=)
MY209754A (en) Amide derivative and preparation method therefore and use thereof in medicine
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
MY196788A (en) Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
WO2016085939A3 (en) Compounds and methods of treating ocular disorders
MX336505B (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
NZ721645A (en) Compounds for use as gpr120 agonists
WO2017165822A8 (en) Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer